Oncocyte(OCX) - 2024 Q4 - Annual Results

Exhibit 99.1 Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. To be clear, this test kit is the assay that we expect ...